Adrenoleukodystrophy) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report

Published: June 21, 2023 Report Code: GDHC7012CTIDB-ST

Select Item

Adrenoleukodystrophy Clinical Trials Analysis Overview

The Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) clinical trial market research report provides an overview of the Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Clinical trials scenario. This report provides top-line data relating to the clinical trials on Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) and includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type. It provides prominent drugs for in-progress trials (based on the number of ongoing trials).

Key Regions ·       North America

·       Asia-Pacific

·       Europe

·       Middle East & Africa

·       South & Central America
Key Countries ·       The US

·       France

·       The UK

·       Germany

·       Netherlands

·       Spain

·       Argentina

·       Australia

·       China

·       Italy
Key Sponsor Types ·       Institution

·       Company

·       Government
Leading Sponsors ·       bluebird bio Inc

·       Ashvattha Therapeutics LLC

·       MedDay SA

·       Minoryx Therapeutics sl

·       Nutra Pharma Corp

·       Poxel SA

·       Magenta Therapeutics Inc

·       SOM Biotech SL

·       Viking Therapeutics Inc

·       Eurofins Scientific SE
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Adrenoleukodystrophy Clinical Trials Market Segmentation by Regions and Countries

The key regions in the Adrenoleukodystrophy clinical trials market are North America, Asia-Pacific, Europe, the Middle East & Africa, and South & Central America, among others. North America dominates the market as of July 2023.

In a country-wise analysis, as of July 2023, the US has the highest number of Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) clinical trials, followed by France, the UK, Germany, Netherlands, Spain, Argentina, Australia, China, and Italy.

G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, France has the highest proportion of Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) to Metabolic Disorders clinical trials as of July 2023. Moreover, most of the clinical trials were conducted in the US.

E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Brazil has the highest proportion of Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) to Metabolic Disorders clinical trials as of July 2023. Out of all the clinical trials conducted in the E7 countries, the majority were in China.

Adrenoleukodystrophy Clinical Trials Analysis by Regions, 2023 (%)

Adrenoleukodystrophy Clinical Trials Analysis by Regions, 2023 (%)

For more regional insights into the Adrenoleukodystrophy clinical trials market, download a free report sample

Adrenoleukodystrophy Clinical Trials Market Segmentation by Sponsor Types

The key sponsor types in the Adrenoleukodystrophy clinical trials market are institution, company, and the government. Out of them, the company sponsor type dominates the market.

Adrenoleukodystrophy Clinical Trials Market Analysis by Sponsor Types, 2023 (%)

Adrenoleukodystrophy Clinical Trials Market Analysis by Sponsor Types, 2023 (%)

For more sponsor type insights into the Adrenoleukodystrophy clinical trials market, download a free report sample

Adrenoleukodystrophy Clinical Trials Market - Competitive Landscape

The leading sponsors in the Adrenoleukodystrophy clinical trials market are bluebird bio Inc, Ashvattha Therapeutics LLC, MedDay SA, Minoryx Therapeutics sl, Nutra Pharma Corp, Poxel SA, Magenta Therapeutics Inc, SOM Biotech SL, Viking Therapeutics Inc, and Eurofins Scientific SE. bluebird bio Inc led the Adrenoleukodystrophy clinical trials market in July 2023.

Adrenoleukodystrophy Clinical Trials Market Analysis by Sponsors, 2023 (%)

Adrenoleukodystrophy Clinical Trials Market Analysis by Sponsors, 2023 (%)

To know more about the leading sponsors in the Adrenoleukodystrophy clinical trials market, download a free report sample

Segments Covered in the Report

Adrenoleukodystrophy Clinical Trials Regional Outlook (2023)

  • North America
  • Asia-Pacific
  • Europe
  • Middle East & Africa
  • South & Central America

Adrenoleukodystrophy Clinical Trials Country Outlook (2023)

  • The US
  • France
  • The UK
  • Germany
  • Netherlands
  • Spain
  • Argentina
  • Australia
  • China
  • Italy

Adrenoleukodystrophy Clinical Trials Sponsor Type Outlook (2023)

  • Institution
  • Company
  • Government

Scope

  • The report provides a snapshot of the global clinical trials landscape

  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type, and End point status

  • The report reviews the top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

  • The report provides all the unaccomplished trials (Terminated, Suspended, and Withdrawn) with a reason for unaccomplishment

  • The report provides enrollment trends for the past five years

  • Report provides the latest news for the past three months

Reasons to Buy

  • Assists in formulating key business strategies with regard to investment

  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost

  • Provides top-level analysis of the Global Clinical Trials Market which helps in identifying key business opportunities

  • Supports understanding of trial count and enrollment trends by country in the global therapeutics market

  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials

  • Facilitates clinical trial assessment of the indication on a global, regional, and country level

bluebird bio Inc
Ashvattha Therapeutics LLC
MedDay SA
Minoryx Therapeutics sl
Nutra Pharma Corp
Poxel SA
Magenta Therapeutics Inc
SOM Biotech SL
Viking Therapeutics Inc
Eurofins Scientific SE

Table of Contents

  • 1. Table of Contents

    • 1.1. List of Tables

    • 1.2. List of Figures

  • 2. Report Guidance

  • 3. GlobalData Clinical Trials Report Coverage

  • 4. Clinical Trials by Region

    • 4.1. Clinical Trials and Average Enrollment by Country

      • 4.1.1. Top Five Countries Contributing to Clinical Trials in Asia-Pacific

      • 4.1.2. Top Five Countries Contributing to Clinical Trials in Europe

      • 4.1.3. Top Countries Contributing to Clinical Trials in North America

      • 4.1.4. Top Five Countries Contributing to Clinical Trials in Middle East and Africa

      • 4.1.5. Top Five Countries Contributing to Clinical Trials in Central and South America

  • 5. Clinical Trials by G7 Countries: Proportion of Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) to Metabolic Disorders Clinical Trials

  • 6. Clinical Trials by Phase in G7 Countries

  • 7. Clinical Trials in G7 Countries by Trial Status

  • 8. Clinical Trials by E7 Countries: Proportion of Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) to Metabolic Disorders Clinical Trials

  • 9. Clinical Trials by Phase in E7 Countries

  • 10. Clinical Trials in E7 Countries by Trial Status

  • 11. Clinical Trials by Phase

    • 11.1. In Progress Trials by Phase

  • 12. Clinical Trials by Trial Status

  • 13. Clinical Trials by End Point Status

  • 14. Subjects Recruited Over a Period of Time

  • 15. Clinical Trials by Sponsor Type

  • 16. Prominent Sponsors

    • 16.1. Top Companies Participating in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials

  • 17. Prominent Drugs

  • 18. Clinical Trial Profile Snapshots

  • 19. Appendix

    • 19.1. Abbreviations

    • 19.2. Definitions

    • 19.3. Research Methodology

    • 19.4. Secondary Research

    • 19.5. About GlobalData

    • 19.6. Contact Us

  • 20. Source

Table

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, Global, Clinical Trials by Region, 2023* 7_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2023* 9_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2023* 10_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2023* 11_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Europe, Top Five Countries, 2023* 12_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, North America, Top Countries, 2023* 13_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2023* 14_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Central and South America, Top Countries, 2023* 15_x000D_

Proportion of Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2023* 17_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, G7 Countries, Clinical Trials by Phase, 2023* 18_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2023* 20_x000D_

Proportion of Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2023* 22_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, E7 Countries, Clinical Trials by Phase, 2023* 23_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2023* 25_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, Global, Clinical Trials by Phase, 2023* 26_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, Global, Clinical Trials In Progress by Phase 2023* 27_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, Global, Clinical Trials by Trial Status, 2023* 29_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Global, by End Point Status, 2023* 30_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2018-2022 31_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2023* 32_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Global, Key Sponsors, 2023* 34_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2023* 36_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2023* 38

Figures

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, Global, Clinical Trials by Region (%), 2023* 7_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2023* 8_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2023* 10_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2023* 11_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2023* 12_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, North America, Top Countries (%), 2023* 13_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2023* 15_x000D_

Proportion of Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) to Metabolic Disorders Clinical Trials, G7 Countries (%), 2023* 16_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, G7 Countries, Clinical Trials by Phase, 2023* 18_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2023* 19_x000D_

Proportion of Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) to Metabolic Disorders Clinical Trials, E7 Countries (%), 2023* 21_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, E7 Countries, Clinical Trials by Phase, 2023* 23_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2023* 24_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, Global, Clinical Trials by Phase (%), 2023* 26_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, Global, Clinical Trials In Progress by Phase, 2023* 27_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics, Global, Clinical Trials by Trial Status, 2023* 28_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Global, by End Point Status, 2023* 30_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2018-2022 31_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2023* 32_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Global, Key Sponsors, 2023* 33_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2023* 35_x000D_

Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2023* 37_x000D_

GlobalData Methodology 83

Frequently asked questions

Adrenoleukodystrophy) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Pharmaceuticals
New
Overweight and Obesity: Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Adrenoleukodystrophy) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update in real time.

  • Access a live Adrenoleukodystrophy) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more